{"id":137458,"date":"2025-08-25T09:34:28","date_gmt":"2025-08-25T13:34:28","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/camed\/?page_id=137458"},"modified":"2025-08-25T09:34:47","modified_gmt":"2025-08-25T13:34:47","slug":"reshma-kewalramni-md-fasn-cas98-camed98","status":"publish","type":"page","link":"https:\/\/www.bumc.bu.edu\/camed\/offices-services\/alumni\/alumni-recognition-resources\/alumni-awards-submission\/past-recipients-of-the-alumni-awards\/reshma-kewalramni-md-fasn-cas98-camed98\/","title":{"rendered":"Reshma Kewalramni, MD, FASN (CAS’98 CAMED’98)"},"content":{"rendered":"

Reshma Kewalramni, MD, FASN (CAS’98 CAMED’98)<\/strong>, is the Chief Execu<\/span>tive Officer and President at Vertex Pharmaceuticals, a Fortune 500, global biotechnology company. Dr. Kewalramani trained in internal medicine and nephrology before entering the biopharmaceutical industry, where she has dedicated her career.<\/p>\n

\"Reshma<\/p>\n

During Dr. Kewalramani\u2019s tenure at the company, Vertex has expanded its success in treating cystic fibrosis (CF), with medicines that hold the potential to treat patients as young as one-month old and as many as 90 percent of all patients diagnosed with CF. Building on that work, Vertex\u2019s R&D pipeline now has treatments in eight disease areas in the clinic, across multiple modalities including small molecule, mRNA, cell and gene therapies. Since 2017, Vertex has doubled its employee base and the number of medicines it offers, significantly expanded its clinical-stage pipeline, and augmented its footprint in Boston\u2019s Seaport and around the world. All the while, Vertex continues to foster its strong culture of inclusion, diversity and equity. <\/span>Continuing the tradition of excellence in the workplace, under Dr. Kewalramani\u2019s leadership, Vertex has consistently been recognized as a best place to work, including by Science<\/em> magazine, The Boston Globe<\/em>, Newsweek<\/em> and Fortune<\/em>. <\/span><\/p>\n

Dr. Kewalramani is committed to supporting biomedical innovation, the next generation of scientists, and her community. She serves on Year Up\u2019s national board of directors, the Biomedical Science Careers Program\u2019s board of directors, the Massachusetts General Hospital board of trustees and the Boston University Chobanian & Avedisian School of Medicine Dean\u2019s Advisory Board. <\/span>She also serves on the Ginkgo Bioworks board of directors, where she chairs the Nominating and Corporate Governance Committee. <\/span><\/p>\n

Dr. Kewalramani completed her internship and residency in internal medicine at the Massachusetts General Hospital, and her fellowship in nephrology at the Massachusetts General Hospital and BrighamWomen\u2019s Hospital combined program. She received her medical degree, with honors, from the seven-year medicine program at the Boston University Chobanian & Avedisian School of Medicine, and is a Fellow of the American Society of Nephrology. <\/span>She is an alumnae of the Harvard Business School, having completed the General Management Program. <\/span><\/p>\n

Dr. Kewalramani has received a number of distinguished honors and awards for her leadership and contributions to science and innovation, including the Harvard Business School Alumni Achievement Award, the International Institute of New England Golden Door Award, the New England Council New Englander of the Year Award, and the Asian American Business Development Center Pinnacle Award. She has been named one of Boston Business Journal<\/em>\u2019s \u201cPower 50,\u201d one of Boston<\/em> magazine\u2019s most influential Bostonians, and one of Business Insider<\/em>\u2019s \u201c10 People Transforming Healthcare.\u201d<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Reshma Kewalramni, MD, FASN (CAS’98 CAMED’98), is the Chief Executive Officer and President at Vertex Pharmaceuticals, a Fortune 500, global biotechnology company. Dr. Kewalramani trained in internal medicine and nephrology before entering the biopharmaceutical industry, where she has dedicated her career. During Dr. Kewalramani\u2019s tenure at the company, Vertex has expanded its success in treating […]<\/p>\n","protected":false},"author":15800,"featured_media":0,"parent":462,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"bu-publication":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/pages\/137458"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/users\/15800"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/comments?post=137458"}],"version-history":[{"count":1,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/pages\/137458\/revisions"}],"predecessor-version":[{"id":137459,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/pages\/137458\/revisions\/137459"}],"up":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/pages\/462"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/media?parent=137458"}],"wp:term":[{"taxonomy":"bu-publication","embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/bu-publication?post=137458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}